+182.8%
HIMS vs GSK
+65.9%
+116.8%
-87.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | GSK | Excess | Alpha |
|---|---|---|---|---|
| 1D | -0.4% | -1.9% | +1.5% | -0.2% |
| 7D | -3.9% | -1.8% | -2.1% | -3.7% |
| 30D | -12.4% | -2.2% | -10.3% | -12.2% |
| 3M | -1.1% | -1.8% | +0.7% | -1.1% |
| 6M | +68.4% | -10.6% | +79.1% | +70.3% |
| YTD | -14.7% | +4.4% | -19.1% | -15.5% |
| 1Y | -42.4% | +30.4% | -72.8% | -45.1% |
| 3Y | +304.5% | +60.1% | +244.5% | +261.9% |
| 5Y | +237.5% | +46.8% | +190.7% | +202.9% |
| All | +182.8% | +65.9% | +116.8% | +149.9% |
Cumulative growth
Daily Returns
Daily percentage return beside GSK.
Daily Out/Under-Performance
Portfolio return minus GSK return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × GSK return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded GSK wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling